Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns

doi:10.1038/s41417-019-0142-6

	Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns
	Ma, Huihui 2,3; Zhao, Chenggang 2,3; Zhao, Zhiyang 2,3; Hu, Lizhu 2,3; Ye, Fang 1; Wang, Hongzhi 1,2; Fang, Zhiyou 1,2; Wu, Yuejin 3,4; Chen, Xueran 1,2
刊名	CANCER GENE THERAPY
	2020-09-01
卷号	27
ISSN号	0929-1903
DOI	10.1038/s41417-019-0142-6
通讯作者	Wu, Yuejin(yjwu@ipp.ac.cn) ; Chen, Xueran(xueranchen@cmpt.ac.cn)
英文摘要	DNA methylation is an important regulator of gene expression, and plays a significant role in carcinogenesis in the brain. Here, we explored specific prognosis-subtypes based on DNA methylation status using 138 Glioblastoma Multiforme (GBM) samples from The Cancer Genome Atlas (TCGA) database. The methylation profiles of 11,637 CpG sites that significantly correlated with survival in the training set were employed for consensus clustering. We identified three GBM molecular subtypes, and their survival curves were distinct from each other. Furthermore, ten feature CpG sites were obtained on conducting a weighted gene co-expression network analysis (WGCNA) of the CpG sites. We were able to classify the samples into high- and low-methylation groups, and classified the prognosis information of the samples after cluster analysis of the training set samples using the hierarchical clustering algorithm. Similar results were obtained in the test set and clinical GBM specimens. Finally, we found that a positive relationship existed between methylation level and sensitivity to temozolomide (or radiotherapy) or anti-migration ability of GBM cells. Taken together, these results suggest that the model constructed in this study could help explain the heterogeneity of previous molecular subgroups in GBM and can provide guidance to clinicians regarding the prognosis of GBM.
WOS关键词	GENE-EXPRESSION ; CANCER ; HYPERMETHYLATION ; PROGRESSION ; BIOMARKERS ; CAPACITY ; MARKERS
WOS研究方向	Biotechnology & Applied Microbiology ; Oncology ; Genetics & Heredity ; Research & Experimental Medicine
语种	英语
出版者	NATURE PUBLISHING GROUP
WOS记录号	WOS:000569884000007
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/104075]
专题	中国科学院合肥物质科学研究院
通讯作者	Wu, Yuejin; Chen, Xueran
作者单位	1.Chinese Acad Sci, Hefei Canc Hosp, Dept Mol Pathol, 350 Shushan Hu Rd, Hefei 230031, Anhui, Peoples R China 2.Chinese Acad Sci, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Ctr Med Phys & Technol, 350 Shushan Hu Rd, Hefei 230031, Anhui, Peoples R China 3.Univ Sci & Technol China, 96 Jin Zhai Rd, Hefei 230026, Anhui, Peoples R China 4.Chinese Acad Sci, Hefei Inst Phys Sci, Inst Tech Biol Agr Engn, 350 Shushan Hu Rd, Hefei 230031, Anhui, Peoples R China
推荐引用方式 GB/T 7714	Ma, Huihui,Zhao, Chenggang,Zhao, Zhiyang,et al. Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns[J]. CANCER GENE THERAPY,2020,27.
APA	Ma, Huihui.,Zhao, Chenggang.,Zhao, Zhiyang.,Hu, Lizhu.,Ye, Fang.,...&Chen, Xueran.(2020).Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.CANCER GENE THERAPY,27.
MLA	Ma, Huihui,et al."Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns".CANCER GENE THERAPY 27(2020).